Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections – Drugs In Development, 2022, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 1, 42, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 3 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

ABAC Therapeutics SA
AEON Medix Inc
Affinivax Inc
Akthelia Pharmaceuticals Ltd
Alterity Therapeutics Ltd
Appili Therapeutics Inc
Armata Pharmaceuticals Inc
BB200 LLC
Bioversys AG
Bugworks Research India Pvt Ltd
Celdara Medical LLC
CHO Pharma Inc
Clarametyx Biosciences Inc
ContraFect Corp
Dong-A ST Co Ltd
Entasis Therapeutics Holdings Inc
F. Hoffmann-La Roche Ltd
Fedora Pharmaceuticals Inc
Forge Therapeutics Inc
GSK plc
Idorsia Pharmaceutical Ltd
Infextious Therapeutic
LimmaTech Biologics AG
Linnaeus Bioscience Inc
Melinta Therapeutics Inc
Microbiotix Inc
Mikrobiomik Healthcare Company SL
Nektr Technologies Ltd
Neoculi Pty Ltd
Nosopharm SAS
Novabiotics Ltd
Oryn Therapeutics
Pedanius Therapeutics Ltd
Peptilogics Inc
Phico Therapeutics Ltd
Planet Biotechnology Inc
Recce Pharmaceuticals Ltd
RemAb Therapeutics SL
Seres Therapeutics Inc
Shionogi & Co Ltd
Soligenix Inc
Spero Therapeutics Inc
Spexis AG
Summit Therapeutics Inc
Syntiron LLC
Taisho Pharmaceutical Holdings Co Ltd
Techulon Inc
VaxNewMO LLC
Venus Medicine Research Centre

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Klebsiella pneumoniae Infections – Overview

Klebsiella pneumoniae Infections – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Klebsiella pneumoniae Infections – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Klebsiella pneumoniae Infections – Companies Involved in Therapeutics Development

Klebsiella pneumoniae Infections – Drug Profiles

Klebsiella pneumoniae Infections – Dormant Projects

Klebsiella pneumoniae Infections – Discontinued Products

Klebsiella pneumoniae Infections – Product Development Milestones

Featured News & Press Releases

Jul 07, 2020: Data published in Ebiomedicine validates novel scientific approach that disarms bacterial defenses to treat or prevent life-threatening infections

Sep 05, 2019: Summit presented in vivo proof of concept data for targeted Enterobacteriaceae antibiotics at ASM/ESCMID Conference

Aug 27, 2019: Vaccine against deadly superbug Klebsiella effective in mice

Aug 20, 2019: Vaxxilon receives grant to develop new prophylactic vaccine

Jul 02, 2019: Appili Therapeutics signs $3M USD grant contract with the United States Department of Defense to develop antibiotics that target superbugs

Apr 03, 2019: Summit’s pipeline expands with series of new mechanism antibiotics targeting Enterobacteriaceae

May 07, 2018: Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria

Apr 17, 2018: Arsanis to Present Abstract On ASN300 At The 28th European Congress of Clinical Microbiology And Infectious Diseases

Nov 07, 2017: Appili Therapeutics Receives $1.2M USD from the Department of Defense to Advance Antibiotic Targeting Drug-Resistant Bacteria

Sep 30, 2017: Development of a negamycin analogue targeting the translational machinery in gram-negative drug-resistant pathogens for the treatment of Infections

Apr 20, 2017: Arsanis Presents Data on ASN-300 at the 27th European Congress of Clinical Microbiology and Infectious Diseases

Apr 11, 2017: Appili Therapeutics Receives Funding from the Government of Canada to Support Development of New Antibiotic To Treat Gram-Negative Infections

Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Klebsiella pneumoniae using Monoclonal Antibody Technology

Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Klebsiella pneumoniae Infections – Pipeline by ABAC Therapeutics SA, 2022

Klebsiella pneumoniae Infections – Pipeline by AEON Medix Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Affinivax Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Akthelia Pharmaceuticals Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Alterity Therapeutics Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Appili Therapeutics Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Armata Pharmaceuticals Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by BB200 LLC, 2022

Klebsiella pneumoniae Infections – Pipeline by Bioversys AG, 2022

Klebsiella pneumoniae Infections – Pipeline by Bugworks Research India Pvt Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Celdara Medical LLC, 2022

Klebsiella pneumoniae Infections – Pipeline by CHO Pharma Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Clarametyx Biosciences Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by ContraFect Corp, 2022

Klebsiella pneumoniae Infections – Pipeline by Dong-A ST Co Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Entasis Therapeutics Holdings Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Fedora Pharmaceuticals Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Forge Therapeutics Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by GSK plc, 2022

Klebsiella pneumoniae Infections – Pipeline by Idorsia Pharmaceutical Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Infextious Therapeutic, 2022

Klebsiella pneumoniae Infections – Pipeline by LimmaTech Biologics AG, 2022

Klebsiella pneumoniae Infections – Pipeline by Linnaeus Bioscience Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Melinta Therapeutics Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Microbiotix Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Mikrobiomik Healthcare Company SL, 2022

Klebsiella pneumoniae Infections – Pipeline by Nektr Technologies Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Neoculi Pty Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Nosopharm SAS, 2022

Klebsiella pneumoniae Infections – Pipeline by Novabiotics Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Oryn Therapeutics, 2022

Klebsiella pneumoniae Infections – Pipeline by Pedanius Therapeutics Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Peptilogics Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Phico Therapeutics Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Planet Biotechnology Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Recce Pharmaceuticals Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by RemAb Therapeutics SL, 2022

Klebsiella pneumoniae Infections – Pipeline by Seres Therapeutics Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Shionogi & Co Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Soligenix Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Spero Therapeutics Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Spexis AG, 2022

Klebsiella pneumoniae Infections – Pipeline by Summit Therapeutics Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by Syntiron LLC, 2022

Klebsiella pneumoniae Infections – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022

Klebsiella pneumoniae Infections – Pipeline by Techulon Inc, 2022

Klebsiella pneumoniae Infections – Pipeline by VaxNewMO LLC, 2022

Klebsiella pneumoniae Infections – Pipeline by Venus Medicine Research Centre, 2022

Klebsiella pneumoniae Infections – Dormant Projects, 2022

Klebsiella pneumoniae Infections – Dormant Projects, 2022 (Contd..1)

Klebsiella pneumoniae Infections – Dormant Projects, 2022 (Contd..2)

Klebsiella pneumoniae Infections – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.